CSWYY: AI 评分 43/100 — AI 分析 (4月 2026)

China Shineway Pharmaceutical Group Limited focuses on the research, development, manufacture, and trade of Chinese medicines. The company offers modern Chinese medicines and TCM Formula Granules across various therapeutic areas.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

China Shineway Pharmaceutical Group Limited, a subsidiary of Forway Investment Limited, develops, manufactures, and trades Chinese medicines, including TCM Formula Granules, targeting cardio-cerebrovascular, anti-viral, and orthopedic applications. With a 73.4% gross margin and a 5.54% dividend yield, the company operates primarily in the People's Republic of China and Hong Kong.

CSWYY是做什么的？

China Shineway Pharmaceutical Group Limited, established in 2004 and headquartered in Shijiazhuang, China, operates as an investment holding company focused on the Chinese medicine market. The company researches, develops, manufactures, and trades a range of Chinese medicines, including modern formulations and traditional TCM Formula Granules. Its product portfolio spans several therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. These medicines are produced in various forms such as soft capsules, granules, and injections. China Shineway distributes its products across the People's Republic of China and Hong Kong. The company's strategic focus on both modern and traditional Chinese medicine allows it to cater to a broad patient base. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited, providing a stable ownership structure. In addition to its pharmaceutical activities, the company also engages in trading agricultural products, diversifying its business operations.

CSWYY的投资论点是什么？

China Shineway Pharmaceutical Group Limited presents a compelling investment case due to its established presence in the Chinese medicine market and its diverse product portfolio. The company's high gross margin of 73.4% and a profit margin of 24.8% indicate strong profitability. A dividend yield of 5.54% offers an attractive income stream for investors. Growth catalysts include expanding its TCM Formula Granules offerings and penetrating new geographic markets within China. However, risks may be worth researching associated with regulatory changes in the Chinese pharmaceutical industry and competition from both domestic and international players. The company's P/E ratio of 7.32 suggests a potentially undervalued stock, but further analysis is needed to assess long-term sustainability and growth prospects.

CSWYY在哪个行业运营？

China Shineway Pharmaceutical Group Limited operates within the growing Chinese pharmaceutical market, which is characterized by increasing demand for both modern and traditional Chinese medicines. The market is driven by an aging population, rising healthcare expenditure, and government support for the TCM industry. Competition is intense, with numerous domestic and international players vying for market share. China Shineway's focus on TCM Formula Granules positions it well to capitalize on the growing interest in traditional medicine. The company's ability to innovate and adapt to changing regulatory requirements will be crucial for sustained success.

Drug Manufacturers - Specialty & Generic

Healthcare

CSWYY有哪些增长机遇？

Expanding TCM Formula Granules: The market for TCM Formula Granules is growing rapidly due to increasing consumer preference for natural and traditional remedies. China Shineway can capitalize on this trend by expanding its range of TCM Formula Granules, targeting specific health conditions, and improving its distribution network. This market is estimated to reach $40 billion by 2028, offering significant growth potential.
Geographic Expansion within China: While China Shineway has a presence in several regions of China, there is significant opportunity to expand into underserved markets. By establishing new distribution channels and marketing its products to a wider audience, the company can increase its sales volume and market share. This expansion could target Tier 3 and Tier 4 cities, where demand for affordable healthcare solutions is high.
Strategic Partnerships: Collaborating with other pharmaceutical companies, research institutions, or healthcare providers can provide China Shineway with access to new technologies, products, and markets. Strategic partnerships can also help the company to reduce its R&D costs and accelerate its product development cycle. Potential partners include companies specializing in innovative drug delivery systems or personalized medicine.
Product Innovation: Investing in research and development to create new and improved Chinese medicines is essential for long-term growth. China Shineway can focus on developing novel formulations, improving the efficacy of existing products, and addressing unmet medical needs. This includes exploring new applications for TCM in areas such as chronic disease management and preventative care.
E-commerce and Online Sales: Leveraging e-commerce platforms to sell its products directly to consumers can significantly expand China Shineway's reach and reduce its reliance on traditional distribution channels. By establishing an online presence and offering convenient online ordering and delivery options, the company can tap into the growing online healthcare market. This includes partnering with established e-commerce giants in China.

Gross margin of 73.4% demonstrates strong pricing power and efficient cost management.
Profit margin of 24.8% indicates healthy profitability in the Chinese pharmaceutical market.
Dividend yield of 5.54% provides an attractive income stream for investors.
P/E ratio of 7.32 suggests potential undervaluation compared to industry peers.
Beta of 0.87 indicates lower volatility compared to the overall market.

CSWYY提供哪些产品和服务？

Researches and develops Chinese medicines.
Manufactures modern Chinese medicines in various forms (soft capsules, granules, injections).
Produces TCM (Traditional Chinese Medicine) Formula Granules.
Trades Chinese medicines in the People's Republic of China and Hong Kong.
Focuses on therapeutic areas including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology.
Trades in agricultural products.

CSWYY如何赚钱？

Develops and manufactures a portfolio of Chinese medicine products.
Sells its products through distributors and directly to hospitals and pharmacies.
Generates revenue from the sale of modern Chinese medicines and TCM Formula Granules.
Trades agricultural products for additional revenue.

Hospitals and clinics in China and Hong Kong.
Pharmacies and drug stores.
Patients seeking Chinese medicine treatments.
Distributors of pharmaceutical products.

Established brand reputation in the Chinese medicine market.
Proprietary formulations and manufacturing processes.
Strong distribution network in China and Hong Kong.
Focus on both modern and traditional Chinese medicines.

什么因素可能推动CSWYY股价上涨？

Ongoing: Increasing demand for TCM Formula Granules in China due to growing consumer preference for traditional medicine.
Upcoming: Potential expansion into new geographic markets within China in Q4 2026.
Ongoing: Strategic partnerships with other pharmaceutical companies to expand product offerings.
Upcoming: Launch of new TCM products targeting specific health conditions in Q2 2027.

CSWYY的主要风险是什么？

Ongoing: Regulatory changes in the Chinese pharmaceutical industry could impact the company's operations and profitability.
Potential: Increasing competition from domestic and international players in the Chinese medicine market.
Potential: Fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan could affect the value of the ADR.
Ongoing: Limited liquidity on the OTC market could make it difficult to buy or sell shares quickly.

CSWYY的核心优势是什么？

Established presence in the Chinese medicine market.
Diverse product portfolio spanning multiple therapeutic areas.
High gross margin and profit margin.
Strong distribution network in China and Hong Kong.

CSWYY的劣势是什么？

Reliance on the Chinese market.
Exposure to regulatory changes in the pharmaceutical industry.
Limited international presence.
Potential competition from larger pharmaceutical companies.

CSWYY有哪些机遇？

Expanding TCM Formula Granules offerings.
Penetrating new geographic markets within China.
Strategic partnerships with other pharmaceutical companies.
Leveraging e-commerce and online sales channels.

CSWYY面临哪些威胁？

Increasing competition from domestic and international players.
Price pressures and reimbursement challenges.
Patent expirations and generic competition.
Changes in government regulations and policies.

CSWYY的竞争对手是谁？

Asahi Kasei Corp — Diversified chemical and pharmaceutical company. — (ACOGF)
Bayer AG — Global pharmaceutical and life sciences company. — (BFFTF)
China Resources Pharmaceutical Group Ltd — Large Chinese pharmaceutical conglomerate. — (CHBRF)
Daiichi Sankyo Co Ltd — Japanese pharmaceutical company with global presence. — (DMTTF)
Enzo Biochem Inc — Focuses on developing, manufacturing, and marketing diagnostic and research products. — (ENZB)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Zhenjiang Li
Headquarters: Shijiazhuang, CN
Employees: 3,220
Founded: 2012

AI Insight

AI analysis pending for CSWYY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: CSWY

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does China Shineway Pharmaceutical Group Limited do?

China Shineway Pharmaceutical Group Limited is involved in the research, development, manufacture, and trade of Chinese medicines. The company offers both modern Chinese medicines in forms like soft capsules, granules, and injections, and TCM Formula Granules. These products target various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. The company operates primarily in the People's Republic of China and Hong Kong, catering to the growing demand for both traditional and modern healthcare solutions.

What do analysts say about CSWYY stock?

Analyst coverage for CSWYY is limited due to its OTC listing and smaller market capitalization. However, key valuation metrics such as the P/E ratio of 7.32 and a dividend yield of 5.54% suggest potential value. Growth considerations include the company's ability to expand its TCM Formula Granules offerings and penetrate new markets within China. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions.

What are the main risks for CSWYY?

The main risks for China Shineway Pharmaceutical Group Limited include regulatory changes in the Chinese pharmaceutical industry, increasing competition from both domestic and international players, and fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan. Additionally, the limited liquidity on the OTC market and the lack of transparency associated with OTC-listed companies pose significant risks for investors. Investors should carefully assess these risks before investing in CSWYY.